Latest Breaking News On - சீனா இணை - Page 7 : comparemela.com

Menicon group forms Shanghai unit for animal medical care business

news Menicon group forms Shanghai unit for animal medical care business 共同通信社 © 共同通信社 Meni-one Co., a group company of major Japanese contact lens maker Menicon Co., has set up a local subsidiary in Shanghai to expand its mainstay animal medical care business in China. The wholly owned unit, Meni-one China Co., was launched last month to respond to growing demand for pet-related goods and services 10 years after Meni-one entered the Chinese market, according to Nagoya-based Menicon. Meni-one, also based in the central Japan city, has been selling animal ophthalmic devices and nutritional supplements in Japan and abroad since its establishment in 2003. The newly formed unit will optimize Meni-one s expertise on pet care and products as the Menicon group is shoring up its business in China, where the bulk of animal medical services have long been provided to livestock such as cattle and pigs.

Menicon coChina coMeni one chinaசீனா இணை

山东能源集团荣膺2021年SAP创新大奖_软件动态_信息化新闻_新闻_e-works数字化企业网

山东能源集团荣膺2021年SAP创新大奖_软件动态_信息化新闻_新闻_e-works数字化企业网
e-works.net.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from e-works.net.cn Daily Mail and Mail on Sunday newspapers.

Clean energyChina institutea innovationInnovation groupChina coInnovation awardsGenesis newInnovation applicationChina instituteசுத்தமான ஆற்றல்கண்டுபிடிப்பு குழுசீனா இணைகண்டுபிடிப்பு விருதுகள்கண்டுபிடிப்பு விண்ணப்பம்சீனா நிறுவனம்

Glenmark s Ryaltris® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age

Glenmark s Ryaltris® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age News provided by Share this article Share this article The launch will ensure much-needed access to a novel fixed-dose combination nasal spray for this chronic condition This marks Glenmark s first innovative product approval in the European Union MUMBAI, India, April 26, 2021 /PRNewswire/ Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris

United kingdomCzech republicSouth koreaSouth africaL vivs ka oblastSaudi arabiaSachin guptaSeqirus ptyMenarini groupEuropean unionLatam glenmark pharmaceuticalsGlenmark pharmaceuticalsHikma pharmaceuticalsChina coBausch healthGlenmark pharmaceuticals limited

Glenmark s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age

Glenmark s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

United kingdomCzech republicSouth africaL vivs ka oblastSaudi arabiaSouth koreaSachin guptaGlenmark ryaltrisSeqirus ptyMenarini groupEuropean unionLatam glenmark pharmaceuticalsGlenmark pharmaceuticalsHikma pharmaceuticalsChina coBausch health

Glenmark Pharma gains after Ryaltris gets approval in Europe

Glenmark Pharmaceuticals rose 1.11% to Rs 565.25 after the company s Ryaltris nasal spray received an approval in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age. The company is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), will shortly be available in Austria, Belgium, Czech Republic, Germany, Denmark, Spain, Finland, France, Ireland, Italy, The Netherlands, Norway, Poland, Romania, Slovakia, Sweden, and the UK. Glenmark will commercialise Ryaltris on its own in select markets. In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark in 2020.

United kingdomCzech republicSouth africaL vivs ka oblastSaudi arabiaSouth koreaSachin guptaMenarini groupEuropean unionLatam glenmark pharmaceuticalsGlenmark pharmaceuticalsHikma pharmaceuticalsChina coBausch healthGrand pharmaceuticalMiddle east